Seeking a measure of clinically meaningful change in ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 5-6, 2014, Pages 398-405

  Mcelhiney, Martin ^a,b   Rabkin, Judith G ^a,b   Goetz, Raymond ^a,b   Katz, Jonathan ^c   Miller, Robert G ^c   Forshew, Dallas A ^c   David, William ^d   Cudkowicz, Merit ^d   Glass, Jonathan D ^e   Appel, Stanley ^f   Simpson, Ericka ^f   Mitsumoto, Hiroshi ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Department of Medicine   (United States)

^c Department of Neurology California Pacific Medical Center   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEUROLOGICAL INSTITUTE   (United States)

Author keywords

ALSFRS R; Clinically meaningful changes; Quality of life

Indexed keywords

ADULT; AGED; ALS FUNCTIONAL RATING SCALE REVISED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CAREGIVER; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DECISION MAKING; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; VERY ELDERLY; CLINICAL TRIAL; DAILY LIFE ACTIVITY; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; CAREGIVERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906346296     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2014.942668     Document Type: Article

References (24)

1. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase III Study Group. Arch Neurol. 1996 53: 1411-47
2. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169: 13-21
3. Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5 (Suppl 1): 90-3
4. Mitsumoto H, Ulug A M, Pullman SL, Gooch CL, Chan S, Tang MX, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007; 68: 1402-10
5. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64: 38-43
6. Traynor B J, Zhang H, Shefner J M, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63: 1933-5
7. Sorenson E, Windbank A J, Mandrekar J, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF-1 is not beneficial in two-year ALS trial. Neurology. 2008; 71: 1770-5
8. Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, et al. Excellent inter-rater, intrarater, and telephone-Administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8: 42-6
9. Kasarskis E J, Dempsey-Hall L, Thompson M M, Luu L C, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6: 50-4
10. Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, et al. Development and evaluationof a self-Administered version of the ALSFRS-R. Neurology. 2006;67: 1294-6
11. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord. 2006;21: 1200-7
12. LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW6002) reduces ' off' time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial. Ann Neurol. 2008;63: 295-302
13. Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, et al. Clinically meaningful differences in patientreported outcomes with amifostine in combination with chemoradiation for locally adVanced non-small-cell lung cancer: An analysis of RTOG 9801. J Radiation Oncology. 2008; 72: 1378-84
14. Burback D, Molnar FJ, St John P, ManSonHing M. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord. 1999;10: 534-40
15. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: A randomized controlled trial. CMAJ. 2006; 174: 1099-105
16. Rockwood K, Black S, Bedard MA, Tran T, Lussier I. Specific symptomatic changes following donepezil treatment of Alzheimer's disease: A multicenter, primary care, openlabel study. Int J Geriatr Psychiatry. 2007;22: 312-9
17. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, et al. Health related quality of life in multiple sclerosis: Effects of natalizumab. Ann Neurol. 2007; 62: 335-46
18. Scivoletto G, Tamburella F, Laurenza L, Molinari M. The spinal cord independence measure: How much change is clinically significant for spinal cord injury subjects. Disability and Rehabilitation. 2013: Early online 1-6
19. Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal clinically meaningful differences for the EORTC QLQ-30 and EORTC QLQ-BN20 scales in brain cancer patients. Annals of Oncology. 2011; 22: 2107-12
20. Polman C, Rudick R. The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability. Neurology. 2010; 74: S8-15
21. Doward L, Dietz B, Wilburn J, McKenna S, Bhor M, Rajagopalan R. Impact of Lipoatrophy on Patient Reported Outcome in Antiretroviral Experienced Patients. The AIDS Reader. 2008: 242-52
22. Raghu G, Collard H, Anstrom K, Flaherty K, Fleming T, King T, et al. Idiopathic pulmonary fibrosis: Clinically meaningful primary endpoints in phase III clinical trials. Amer J of Respiratory and Critical Care Medicine. 2012; 185: 1044-8
23. Gordon P. Cheng B, Montes J, Doorish, Albert S, Mitsumoto H. Outcome measures for early phase clinical trials. Amyotroph Lateral Scler. 2007; 8: 270-3
24. Kiresuk T, Smith A, Cardillo J, eds. Goal Attainment Scaling: Applications, Theory and Measurement. NJ: Erlbaum, 1994